Human antibodies made in genetically engineered cows have proved safe in an early-stage clinical trial.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Momenta Pharmaceuticals and Mylan plan to begin a pivotal clinical study of a biosimilar to Regeneron’s blockbuster eye drug Eylea in first-half 2018.
Sangamo Therapeutics Inc. and Pfizer Inc. are partnering to develop a gene therapy to treat a disease that affects nerve cells in the brain and the spinal cord.
Normal immune cells that live near milk ducts in healthy breast tissue may play a key role in helping early breast cancer cells leave the breast for other parts of the body, researchers say.
People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.
People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.
Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.
Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who do not use these supplements per a research review.
Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.
The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.
Shire’s experimental treatment SHP609 to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial.
Allergan and Gedeon Richter’s drug cariprazine to treat severe bipolar depression in adults met the main goal of a late-stage study.
Merck & Co.’s Keytruda came up short in a pivotal study as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
2017 has shaped up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.
At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.
The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.
Eli Lilly & Co.’s Cyramza met the main study goal but failed to improve survival rates in a late-stage trial for gastric cancer.
Pfizer’s talazoparib for advanced breast cancer was demonstrated to be superior to chemotherapy in a late-stage study.
Roche scientists may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.
Sage Therapeutics Inc.’s drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.